

APPLE 2021_Free Paper VOD Presentation

No	Abstract No.	Subject	Name	Institution
Artificial Intelligence (AI)				
FV-01	72	Automated Segmentation on Multiphase Computed Tomography Simulation in Radiotherapy to Liver Cancer Using Three-Dimensional Deep Neural Networks	Shao-Lun Lu	National Taiwan University Hospital
Biomarkers				
FV-02	76	Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma	Jiang He	Fudan University
Cell Biology and Translational Research				
FV-03	50	YAP/TAZ Expression in Hepatocellular Carcinoma (HCC) and Effects of YAP/TAZ Inhibition on HCC	Sojung Han	Eulji University
FV-04	66	Orchestrating the Spatial and Single-cell Immune Landscape of Colorectal Cancer Liver Metastasis	Yingcheng Wu	Fudan University
FV-05	74	CircTUBD1 Regulates Radiation-induced Hepatic Stellate Cell Activation and Profibrotic Response via a CircTUBD1/Micro-203a-3p/Smad3 Positive Feedback Loop	Hao Niu	Fudan University
FV-06	75	Long Non-coding RNA LINC00601 Contributes to Oxaliplatin Resistance of Hepatocellular Carcinoma Cells via Targeting GADD45A Gene Pathways	Keshu Hu	Fudan University
Diagnosis and Liver Imaging				
FV-07	68	Early Complete Tumor Response as a Survival Predictor In Hepatocellular Carcinoma Patients Receiving Stereotactic Body Radiation Therapy	Qi-Qiao Wu	Fudan University
Epidemiology and Surveillance				
FV-08	46	Portal Vein Thrombosis in Pakistani Population with Hepatocellular Carcinoma – Prevalence and Risk Factors	Tayyab ul Hassan Siddiqui	Aga Khan University
Molecular Pathogenesis and Pathology				
FV-09	27	Dysregulation of RalA Signaling through Dual Regulatory Mechanisms Exerts Its Oncogenic Functions in Hepatocellular Carcinoma	Tian Lu	The University of Hong Kong
FV-10	80	Cancer Testis Antigen PAGE4 on Tumor-associated Macrophages promotes Invasion and Metastasis of CTNNB1-mutated Hepatocellular Carcinoma via CD36	Juan Zhang	Fudan University
FV-11	94	Activation of the NLRP3 Inflammasome in Hepatitis C Virus-related Hepatocellular Carcinoma: Relation to Oxidative Stress and Tumor Progression	Hoda El Aggan	Alexandria University
Staging and Prognosis				
FV-12	31	Pattern and Clinical Significance of Lymph Node Metastasis from Hepatocellular Carcinoma	Byung min Lee	Yonsei University
FV-13	55	A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma	Shu-Yein Ho	Min-Sheng General Hospital
FV-14	73	Identification of a Pyroptosis-related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma	Su Su Zheng	Fudan University
Treatment: Clinical Trials				
FV-15	7	Lenvatinib Plus Pembrolizumab for Patients with Previously Treated Biliary Tract Cancers in the Multicohort Phase 2 LEAP-005 Study	Hyun Cheol Chung	Yonsei University
FV-16	87	Atezolizumab plus bevacizumab (A+B) for patients with unresectable hepatocellular carcinoma (HCC) and chronic hepatitis B virus (HBV) infection with high viral load	San-Chi Chen	Taipei Veterans General Hospital
Treatment: Novel Target or Experimental Therapy				
FV-17	28	Nano-delivery of Simvastatin to Liver Sinusoidal Endothelial Cells Inhibits Hepatocellular Carcinoma via Tumor Microenvironment Remodeling	Zhuo Yu	Shanghai University
FV-18	29	Bufalin Stimulates Immune Response in Hepatocellular Carcinoma by Reprogramming Tumor-Infiltrating Macrophage toward M1 Phenotype	Hai Feng	Shanghai University
Treatment: Surgical Resection and Transplantation				
FV-19	2	Outcomes of Living Donor Liver Transplantation in Patients with a History of Ruptured Hepatocellular Carcinoma	Suk Kyun Hong	Seoul National University
FV-20	23	Surgical Outcomes of Fibrolamellar Hepatocellular Carcinoma Patients: SEER Database Study	Tomoki Sempokuya	University of Nebraska Medical Center

APPLE 2021_Free Paper VOD Presentation

No	Abstract No.	Subject	Name	Institution
FV-21	52	Comparison of Clinical Outcome between Minimally Invasive and Open Hepatectomy at High Difficulty Score for Hepatocellular Carcinoma	Kelvin K.C. Ng	The Chinese University of Hong Kong
FV-22	71	Long-term Survival of Elderly Patients Undergoing Curative Liver Resection for Early-stage Hepatocellular Carcinoma An International Multicenter Competing Risk Analysis	Tian Yang	Second Military Medical University
Treatment: Systemic or Targeted Therapy				
FV-23	19	Early Serum Tumor Marker Responses Predict the Efficacy of Lenvatinib plus an Anti-PD-1 Antibody in Unresectable Hepatocellular Carcinoma	Xiao-Dong Zhu	Fudan University
FV-24	30	Prognosis and Second-Line Treatment Outcome of Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab and Bevacizumab Treatment	Ching-Tso Chen	National Taiwan University
FV-25	51	Effects of Combination Therapy using Lenvatinib and an Anti-PD-1 Antibody on Liver Function in Patients with Advanced Hepatocellular Carcinoma	Ying-Hao Shen	Fudan University
FV-26	63	Chemoprevention of Recurrent Hepatocellular Carcinoma after Liver Resection May be Possible with Aspirin in Diabetic Patients	Larry Ray Hromalik Jr.	University of Hawaii John A. Burns
FV-27	85	Adjuvant Lenvatinib After Radical Resection in Patients with Hepatocellular Carcinoma (HCC): Preliminary Analysis of a Prospective, Multi-center, Single-Arm Study	Hui-Chuan Sun	Fudan University
FV-28	86	Lenvatinib (LEN) plus Anti-PD-1 Antibodies in Patients with Unresectable Hepatocellular Carcinoma (uHCC) Who Progressed on Front-line LEN: Real-world Data from China	Lan Zhang	Fudan University
Treatment: Transarterial Approach/Percutaneous Ablative Therapy/Radiation Therapy				
FV-29	17	Liver-directed Concurrent Chemoradiotherapy versus Sorafenib for BCLC Stage C Hepatocellular Carcinoma	Jina Kim	Yonsei University
FV-30	21	Etiology-dependent Tumor Control Probability Model after Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study	Nalee Kim	Sungkyunkwan University
FV-31	34	Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and Right Atrium Treated with Palliative Radiation Therapy and Lenvatinib	Adeodatus Vito Nicanor	Makati Medical Center
FV-32	70	Development and Validation of A Novel Online Calculator for Estimating Survival Benefit of Adjuvant Transcatheter Arterial Chemoembolization in Patients Undergoing Surgery for Hepatocellular Carcinoma Undergoing Surgery for Hepatocellular Carcinoma	Tian Yang	Eastern Hepatobiliary Surgery Hospital
FV-33	77	Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients with Main Portal Vein Tumor Thrombus Receiving Conventional Transarterial Chemoembolization: an Analysis of 173 Patients	Jing-huan Li	Fudan University
FV-34	78	Development of a Prognostic Score for Recommended TACE Candidates with Hepatocellular Carcinoma Spontaneous Rupture	Jixue Zou	Fudan University
FV-35	79	Establishment of a Nomogram for Prognostic Prediction in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization	Zhongchen Li	Fudan University
Viral Hepatitis				
FV-36	11	Bioinformatics Study of Genes E1 and E2 from Hepatitis C Virus (HCV) with Genotypes 1, 2, 3 and 6 as Vaccine Candidates for Virus-like particles (VLPs)	Rifaldy Fajar	Yogyakarta State University
Other Hepatobiliary Diseases				
FV-37	88	Via mTOR Signaling Pathway LONP1 Protects Hepatocyte Oxidative Damage through Increase of Gluconeogenesis	Mu-Chen Wu	Beijing You-An Hospital
Miscellaneous				
FV-38	10	Risk Factors of Diabetes mellitus (DM) in Hepatocellular Carcinoma in Sultan Daeng Raja Hospital, Bulukumba Regency	Sahnaz Vivinda Putri	International University Semen Indonesia